{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T19:47:48Z","timestamp":1773431268036,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"crossref","award":["2021JQ-912"],"award-info":[{"award-number":["2021JQ-912"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shaanxi Provincial People\u2019s Hospital Talent Support Program","award":["2022JY-13"],"award-info":[{"award-number":["2022JY-13"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-025-05066-8","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:58:32Z","timestamp":1759229912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic overcoming of cisplatin resistance in ovarian cancer by combined Astragalus Membranaceus and cisplatin treatment: network pharmacology and experimental validation"],"prefix":"10.1186","volume":"25","author":[{"given":"Fei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-fang","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-liang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"5066_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00592","volume":"8","author":"G Kalamegam","year":"2018","unstructured":"Kalamegam G, Sait KHW, Ahmed F, Kadam R, Pushparaj PN, Anfinan N, et al. Human wharton\u2019s jelly stem cell (hWJSC) extracts inhibit ovarian cancer cell lines OVCAR3 and SKOV3 in vitro by inducing cell cycle arrest and apoptosis. Front Oncol. 2018;8: 592.","journal-title":"Front Oncol"},{"issue":"6","key":"5066_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.936","volume":"5","author":"A Mazidimoradi","year":"2022","unstructured":"Mazidimoradi A, Momenimovahed Z, Allahqoli L, Tiznobaik A, Hajinasab N, Salehiniya H, et al. The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer. Health Sci Rep. 2022;5(6): e936.","journal-title":"Health Sci Rep"},{"issue":"1","key":"5066_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s10020-020-00174-2","volume":"26","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Yan G, Lei J, Chen Y, Wang T, Gong J, et al. The SP1-12LOX axis promotes chemoresistance and metastasis of ovarian cancer. Mol Med. 2020;26(1):39.","journal-title":"Mol Med"},{"issue":"10177","key":"5066_CR4","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240\u201353.","journal-title":"Lancet"},{"issue":"15","key":"5066_CR5","doi-asserted-by":"publisher","first-page":"10043","DOI":"10.1021\/acs.chemrev.7b00042","volume":"117","author":"J Zielonka","year":"2017","unstructured":"Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, et al. Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev. 2017;117(15):10043\u2013120.","journal-title":"Chem Rev"},{"issue":"3","key":"5066_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/rb\/rbab015","volume":"8","author":"Q Wang","year":"2021","unstructured":"Wang Q, Wu C, Li X, Yang D, Shi L. Cisplatin and Paclitaxel co-delivery nanosystem for ovarian cancer chemotherapy. Regen Biomater. 2021;8(3): rbab015.","journal-title":"Regen Biomater"},{"issue":"15","key":"5066_CR7","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869\u201383.","journal-title":"Oncogene"},{"key":"5066_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114205","volume":"232","author":"M Song","year":"2022","unstructured":"Song M, Cui M, Liu K. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem. 2022;232: 114205.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"5066_CR9","doi-asserted-by":"publisher","first-page":"e183773","DOI":"10.1001\/jamaoncol.2018.3773","volume":"5","author":"G Falchook","year":"2019","unstructured":"Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, et al. Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2019;5(1):e183773.","journal-title":"JAMA Oncol"},{"issue":"1","key":"5066_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40659-019-0243-6","volume":"52","author":"L Liu","year":"2019","unstructured":"Liu L, Fan J, Ai G, Liu J, Luo N, Li C, et al. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells. Biol Res. 2019;52(1):37.","journal-title":"Biol Res"},{"issue":"1","key":"5066_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s13046-019-1360-3","volume":"38","author":"SS Islam","year":"2019","unstructured":"Islam SS, Aboussekhra A. Sequential combination of cisplatin with Eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway. J Exp Clin Cancer Res. 2019;38(1):382.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"5066_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1142\/S0192415X16500014","volume":"44","author":"KK Auyeung","year":"2016","unstructured":"Auyeung KK, Han QB, Ko JK. Astragalus membranaceus: a review of its protection against inflammation and gastrointestinal cancers. Am J Chin Med. 2016;44(1):1\u201322.","journal-title":"Am J Chin Med"},{"key":"5066_CR13","doi-asserted-by":"publisher","first-page":"153698","DOI":"10.1016\/j.phymed.2021.153698","volume":"91","author":"A Sheik","year":"2021","unstructured":"Sheik A, Kim K, Varaprasad GL, Lee H, Kim S, Kim E, et al. The anti-cancerous activity of adaptogenic herb astragalus membranaceus. Phytomedicine. 2021;91:153698.","journal-title":"Phytomedicine"},{"key":"5066_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jep.2018.12.003","volume":"232","author":"Y Chen","year":"2019","unstructured":"Chen Y, Bi L, Luo H, Jiang Y, Chen F, Wang Y, et al. Water extract of ginseng and astragalus regulates macrophage polarization and synergistically enhances ddp\u2019s anticancer effect. J Ethnopharmacol. 2019;232:11\u201320.","journal-title":"J Ethnopharmacol"},{"key":"5066_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jep.2018.04.014","volume":"221","author":"J Zhang","year":"2018","unstructured":"Zhang J, Liu L, Wang J, Ren B, Zhang L, Li W. Formononetin, an isoflavone from astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells. J Ethnopharmacol. 2018;221:91\u20139.","journal-title":"J Ethnopharmacol"},{"key":"5066_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1334915","volume":"14","author":"Q Yang","year":"2024","unstructured":"Yang Q, Meng D, Zhang Q, Wang J. Advances in research on the anti-tumor mechanism of astragalus polysaccharides. Front Oncol. 2024;14: 1334915.","journal-title":"Front Oncol"},{"key":"5066_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1755-8794-2-34","volume":"2","author":"M Li","year":"2009","unstructured":"Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 2009;2:34.","journal-title":"BMC Med Genomics"},{"issue":"3","key":"5066_CR18","doi-asserted-by":"publisher","first-page":"e0151089","DOI":"10.1371\/journal.pone.0151089","volume":"11","author":"W Chowanadisai","year":"2016","unstructured":"Chowanadisai W, Messerli SM, Miller DH, Medina JE, Hamilton JW, Messerli MA, et al. Cisplatin resistant spheroids model clinically relevant survival mechanisms in ovarian tumors. PLoS One. 2016;11(3):e0151089.","journal-title":"PLoS One"},{"key":"5066_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.taap.2016.08.005","volume":"310","author":"N Arrighetti","year":"2016","unstructured":"Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, et al. PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. Toxicol Appl Pharmacol. 2016;310:9\u201319.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"5066_CR20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12967-018-1593-5","volume":"16","author":"DD Xiong","year":"2018","unstructured":"Xiong DD, Dang YW, Lin P, Wen DY, He RQ, Luo DZ, et al. A circRNA-miRNA-mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma. J Transl Med. 2018;16(1):220.","journal-title":"J Transl Med"},{"key":"5066_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1758-2946-6-13","volume":"6","author":"J Ru","year":"2014","unstructured":"Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:13.","journal-title":"J Cheminform"},{"issue":"W1","key":"5066_CR22","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216\u201321.","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"5066_CR23","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A web server for comprehensive analysis of Tumor-Infiltrating immune cells. Cancer Res. 2017;77(21):e108\u201310.","journal-title":"Cancer Res"},{"key":"5066_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jphotobiol.2018.04.039","volume":"183","author":"SS Erdem","year":"2018","unstructured":"Erdem SS, Obeidin VA, Yigitbasi T, Tumer SS, Yigit P. Verteporfin mediated sequence dependent combination therapy against ovarian cancer cell line. J Photochem Photobiol B. 2018;183:266\u201374.","journal-title":"J Photochem Photobiol B"},{"key":"5066_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.780387","volume":"11","author":"H Ji","year":"2021","unstructured":"Ji H, Li K, Xu W, Li R, Xie S, Zhu X. Prediction of the mechanisms by which Quercetin enhances cisplatin action in cervical cancer: a network pharmacology study and experimental validation. Front Oncol. 2021;11: 780387.","journal-title":"Front Oncol"},{"issue":"1","key":"5066_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13048-019-0578-1","volume":"12","author":"J Shen","year":"2019","unstructured":"Shen J, Yu S, Sun X, Yin M, Fei J, Zhou J. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis. J Ovarian Res. 2019;12(1):110.","journal-title":"J Ovarian Res"},{"issue":"10214","key":"5066_CR27","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","volume":"394","author":"AR Clamp","year":"2019","unstructured":"Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O\u2019Donnell DM, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019;394(10214):2084\u201395.","journal-title":"Lancet"},{"key":"5066_CR28","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8293","author":"L Yang","year":"2022","unstructured":"Yang L, Xie HJ, Li YY, Wang X, Liu XX, Mai J. Molecular mechanisms of platinum\u2013based chemotherapy resistance in ovarian cancer (review). Oncol Rep. 2022. https:\/\/doi.org\/10.3892\/or.2022.8293.","journal-title":"Oncol Rep"},{"key":"5066_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242317046","author":"P Geng","year":"2023","unstructured":"Geng P, Zhao J, Li Q, Wang X, Qin W, Wang T, et al. Z-ligustilide combined with cisplatin reduces PLPP1-mediated phospholipid synthesis to impair cisplatin resistance in lung cancer. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms242317046.","journal-title":"Int J Mol Sci"},{"key":"5066_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154776","volume":"115","author":"X Niu","year":"2023","unstructured":"Niu X, Shi Y, Li Q, Chen H, Fan X, Yu Y, et al. Ginsenoside Rb(1) for overcoming cisplatin-insensitivity of A549\/DDP cells in vitro and vivo through the dual-inhibition on two efflux pumps of ABCB1 and PTCH1. Phytomedicine. 2023;115: 154776.","journal-title":"Phytomedicine"},{"key":"5066_CR31","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.2147\/DDDT.S288707","volume":"15","author":"S Sarwar","year":"2021","unstructured":"Sarwar S, Alamro AA, Alghamdi AA, Naeem K, Ullah S, Arif M, et al. Enhanced accumulation of cisplatin in ovarian cancer cells from combination with Wedelolactone and resulting Inhibition of multiple epigenetic drivers. Drug Des Devel Ther. 2021;15:2211\u201327.","journal-title":"Drug Des Devel Ther"},{"key":"5066_CR32","doi-asserted-by":"publisher","first-page":"9335440","DOI":"10.1155\/2023\/9335440","volume":"2023","author":"D Wang","year":"2023","unstructured":"Wang D, Tang X, Ruan J, Zhu Z, Wang R, Weng Y, et al. HSP90AB1 as the druggable target of maggot extract reverses cisplatin resistance in ovarian cancer. Oxid Med Cell Longev. 2023;2023:9335440.","journal-title":"Oxid Med Cell Longev"},{"key":"5066_CR33","doi-asserted-by":"crossref","unstructured":"Chen Z, Giotti B, Kaluzova M, Vallcorba MP, Rawat K, Price G et al. A paracrine circuit of IL-1beta\/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression. J Clin Invest. 2023;133(22):e163802.","DOI":"10.1172\/JCI163802"},{"key":"5066_CR34","doi-asserted-by":"publisher","first-page":"1211730","DOI":"10.3389\/fimmu.2023.1211730","volume":"14","author":"ZH Chew","year":"2023","unstructured":"Chew ZH, Cui J, Sachaphibulkij K, Tan I, Kar S, Koh KK, et al. Macrophage IL-1beta contributes to tumorigenesis through paracrine AIM2 inflammasome activation in the tumor microenvironment. Front Immunol. 2023;14:1211730.","journal-title":"Front Immunol"},{"issue":"6","key":"5066_CR35","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00404-017-4547-x","volume":"296","author":"JX Pan","year":"2017","unstructured":"Pan JX, Qu F, Wang FF, Xu J, Mu LS, Ye LY, et al. Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer. Arch Gynecol Obstet. 2017;296(6):1145\u201352.","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"5066_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.bbagen.2010.03.013","volume":"1800","author":"ME Janik","year":"2010","unstructured":"Janik ME, Litynska A, Vereecken P. Cell migration-the role of integrin glycosylation. Biochim Biophys Acta. 2010;1800(6):545\u201355.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"5066_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6712","volume":"5","author":"J Muller","year":"2014","unstructured":"Muller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5(1): 5712.","journal-title":"Nat Commun"},{"key":"5066_CR38","doi-asserted-by":"crossref","unstructured":"Rebe C, Ghiringhelli F. Interleukin-1beta and cancer. Cancers (Basel). 2020;12(7):1791.","DOI":"10.3390\/cancers12071791"},{"key":"5066_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1121130","volume":"13","author":"X Zhai","year":"2023","unstructured":"Zhai X, Pu D, Wang R, Zhang J, Lin Y, Wang Y, et al. Gas6\/AXL pathway: immunological landscape and therapeutic potential. Front Oncol. 2023;13: 1121130.","journal-title":"Front Oncol"},{"key":"5066_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13106","author":"L Han","year":"2021","unstructured":"Han L, Fu Q, Deng C, Luo L, Xiang T, Zhao H. Immunomodulatory potential of flavonoids for the treatment of autoimmune diseases and tumour. Scand J Immunol. 2021. https:\/\/doi.org\/10.1111\/sji.13106.","journal-title":"Scand J Immunol"},{"issue":"7","key":"5066_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202200435","volume":"67","author":"N Duan","year":"2023","unstructured":"Duan N, Hu X, Zhou R, Li Y, Wu W, Liu N. A review on dietary flavonoids as modulators of the tumor microenvironment. Mol Nutr Food Res. 2023;67(7): e2200435.","journal-title":"Mol Nutr Food Res"},{"issue":"1","key":"5066_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12906-021-03425-9","volume":"21","author":"Z Liu","year":"2021","unstructured":"Liu Z, Ma H, Lai Z. Revealing the potential mechanism of astragalus Membranaceus improving prognosis of hepatocellular carcinoma by combining transcriptomics and network pharmacology. BMC Complement Med Ther. 2021;21(1):263.","journal-title":"BMC Complement Med Ther"},{"key":"5066_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.112797","volume":"258","author":"S Li","year":"2020","unstructured":"Li S, Sun Y, Huang J, Wang B, Gong Y, Fang Y, et al. Anti-tumor effects and mechanisms of astragalus membranaceus (AM) and its specific immunopotentiation: status and prospect. J Ethnopharmacol. 2020;258: 112797.","journal-title":"J Ethnopharmacol"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-05066-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-025-05066-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-05066-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:58:35Z","timestamp":1759229915000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-025-05066-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5066"],"URL":"https:\/\/doi.org\/10.1186\/s12906-025-05066-8","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and the Shaanxi Provincial People\u2019s Hospital Medical Ethics Committee approved it (approval code: 2023\u00a0K-S069).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"337"}}